Stat

PROTAC STAT3 degrader-3 (S3D1) targets the STAT3 protein through a PROTAC-mediated degradation mechanism. This compound exhibits potent anticancer activity by facilitating the ubiquitination and subsequent proteasomal degradation of STAT3, a key oncogenic transcription factor. It is primarily applied in research focused on cancer biology, particularly in studies investigating the therapeutic potential of targeting the STAT3 signaling pathway.

DM243 is an EPAC1 activator and STAT3 modulator known for its ability to increase GTP-bound Rap1 levels specifically in EPAC1-expressing cells, while exhibiting no effects on EPAC2 or PKA. This compound effectively reduces IL-6/IL-6Rα-induced STAT3 phosphorylation in endothelial cells and suppresses TGF-β1-mediated fibroblast-to-myofibroblast transition, leading to decreased levels of α-smooth muscle actin and Collagen I in lung fibroblasts. Additionally, DM243 demonstrates minimal cytotoxicity in normal human lung fibroblasts, making it a valuable tool for studies related to fibrosis and inflammation.

Phenylpyropene C is a JAK/STAT pathway inhibitor known to effectively inhibit interferon-gamma (IFN-γ) mediated expression of reporter genes, with an IC50 range of 5.4 to 10.8 μM. Additionally, it serves as an inhibitor of acyl-CoA, exhibiting an IC50 of 16.0 μM. This compound is valuable for research applications focusing on the modulation of immune responses and the exploration of cytokine signaling pathways.

STAT3-IN-26 is a selective ligand for the transcription factor STAT3, a critical regulator of cell growth and survival. This compound is instrumental in the synthesis of PROTACs (Proteolysis-targeting chimeras) aimed at inducing the degradation of STAT3. It is particularly relevant for research into targeted cancer therapies and studies on cellular signaling pathways involving STAT3.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

YN11 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with a Kd of 11.9 μM. By directly binding to the SH2 domain, YN11 effectively inhibits the phosphorylation of STAT3, leading to decreased expression of downstream target proteins. This compound has demonstrated significant biological activity, inducing cell cycle arrest and promoting apoptosis in prostate cancer cells, while also inhibiting cell invasion and migration. In vivo studies indicate that YN11 suppresses tumor growth in prostate cancer xenograft models without causing significant body weight loss or histopathological changes in major organs, making it a valuable tool for research in prostate cancer therapy.